Division of Pediatric Hematology/Oncology, Washington University School of Medicine, St. Louis, MO, United States.
Front Immunol. 2020 Oct 19;11:567423. doi: 10.3389/fimmu.2020.567423. eCollection 2020.
The variables that influence the selection of a preparative regimen for a pediatric hematopoietic stem cell transplant procedure encompasses many issues. When one considers this procedure for non-malignant diseases, components in a preparative regimen that were historically developed to reduce malignant tumor burden may be unnecessary. The primary goal of the procedure in this instance becomes engraftment with the establishment of normal hematopoiesis and a normal immune system. Overcoming rejection becomes the primary priority, but pursuit of this goal cannot neglect organ toxicity, or post-transplant morbidity such as graft-versus-host disease or life threatening infections. With the improvements in supportive care, newborn screening techniques for early disease detection, and the expansion of viable donor sources, we have reached a stage where hematopoietic stem cell transplantation can be considered for virtually any patient with a hematopoietic based disease. Advancing preparative regiments that minimize rejection and transplant related toxicity will thus dictate to what extent this medical technology is fully utilized. This mini-review will provide an overview of the origins of conditioning regimens for transplantation and how agents and techniques have evolved to make hematopoietic stem cell transplantation a viable option for children with non-malignant diseases of the hematopoietic system. We will summarize the current state of this facet of the transplant procedure and describe the considerations that come into play in selecting a particular preparative regimen. Decisions within this realm must tailor the treatment to the primary disease condition to ideally achieve an optimal outcome. Finally, we will project forward where advances are needed to overcome the persistent engraftment obstacles that currently limit the utilization of transplantation for haematopoietically based diseases in children.
影响儿科造血干细胞移植方案选择的变量涵盖了许多问题。当考虑到非恶性疾病的这种程序时,历史上为减少恶性肿瘤负担而开发的预备方案中的成分可能是不必要的。在这种情况下,该程序的主要目标是通过建立正常造血和正常免疫系统来进行植入。克服排斥成为首要任务,但追求这一目标不能忽视器官毒性,或移植后发病率,如移植物抗宿主病或威胁生命的感染。随着支持性护理的改善、早期疾病检测的新生儿筛查技术以及可行供体来源的扩大,我们已经达到了可以考虑为几乎任何患有基于血液疾病的患者进行造血干细胞移植的阶段。因此,推进最大限度减少排斥和移植相关毒性的预备方案将决定这项医疗技术在多大程度上得到充分利用。这篇迷你综述将概述移植用预处理方案的起源,以及药物和技术如何发展,使造血干细胞移植成为血液系统非恶性疾病儿童的可行选择。我们将总结目前这种移植程序的现状,并描述在选择特定预备方案时需要考虑的因素。在这个领域内的决策必须根据主要疾病状况来调整治疗,以理想地达到最佳结果。最后,我们将预测目前限制基于血液疾病在儿童中移植应用的持续植入障碍需要在哪些方面取得进展。